$ELMD

Nagel Bradley M. sold $429K of ELMD

Nagel Bradley M. (Chief Financial Officer) sold 11,801 shares of Electromed, Inc. (ELMD) at an average of $36.35 ($36.34–$37.11, $0.43M total) across 2 trades on 2026-06-04.

Original reporting
SEC EDGAR · Nagel Bradley M.
Published Jun 8, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 9:51 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ELMD
Neutral
high confidence
Mentioned
$ELMD
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ELMDNeutralLow
01

Why it matters

The newest fact is the CFO’s open-market sale of 11,801 shares for about $428,936, with holdings after the sale of 19,638 shares.

02

Market read

Traders may note the insider sale, but the filing lacks any accompanying fundamental or regulatory catalyst.

03

What to watch

The article provides no context on total insider holdings, tax planning, or whether other insiders sold/bought around the same time.

Relevance 4/10Novelty 3/10Timing: filed 2026-06-08, transaction dated 2026-06-04

Background

The article is an SEC Form 4 insider transaction disclosure for Electromed, Inc. (ELMD).

Company-level read

Ticker impact

$ELMDNeutralHigh confidence
Context

Electromed CFO Nagel Bradley M. sold about $429K of ELMD shares in an open-market transaction disclosed via Form 4.

Expected impact

Low likelihood of a sustained price move; any reaction would be short-lived unless followed by additional disclosures.

Evidence & confidence

The filing is a Form 4 open-market sale, with no 10b5-1 plan and no accompanying company-specific news in the text.

Market effects

No sector-level implications from a single insider sale disclosure.

None indicated.

None indicated.

Counterpoint

Insider sales can be interpreted as liquidity-driven rather than bearish, especially when not tied to a broader negative company event.

Key entities

  • Electromed, Inc.

    Company whose insider transaction is disclosed on Form 4.

  • Nagel Bradley M.

    Chief Financial Officer who sold ELMD shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Electromed, Inc. Q4 2026 Earnings Call Summary

Electromed, Inc. reported 15% Q4 home care revenue growth and 29% hospital revenue decline, driven by sales and longer sales cycles. The company expects double-digit growth in 2027, with strategic investments in digital solutions and sales force expansion. CEO James Cunniff will retire in April 2027. The company aims to expand payer coverage and product lines.

$ELMDMed

Electromed, Inc. (ELMD): Results of Operations and Financial Condition

Electromed, Inc. (ELMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Electromed, Inc. Announces Record Fiscal 2026 Fourth Quarter and Full Year Financial Results Strong homecare revenue growth and expanded operating leverage drive record operating income in Fiscal 2026 NEW PRAGUE, Minn.--(BUSINESS WIRE)-- Electromed, Inc. (“Electromed